| ID . | Age . | Number of trastuzumab cycle . | Baseline LVEF (%) . | Nadir LVEF (%) . | Relative GLS drop (%) . | Hospitali- zation . | Worst NYHA . | Metastasis/ progression . | Cumulative anthracycline dose (mg/m2) . | Reason for permanent trastuzumab discontinuation . |
|---|---|---|---|---|---|---|---|---|---|---|
| 43 | 65 | 9 | 67.3 | 46.7 | 24.3 | Yes | II | No | 486* | Symptomatic severe mitral regurgitation |
| 23 | 65 | 9 | 58.2 | 25.9 | 62 | Yes | III | No | 266 | Continuous worsening of LV function with multi-valvular abnormalities |
| 29 | 35 | 12 | 55 | 28 | 47 | No | I | No | 253 | Continuous worsening of LV function |
| ID . | Age . | Number of trastuzumab cycle . | Baseline LVEF (%) . | Nadir LVEF (%) . | Relative GLS drop (%) . | Hospitali- zation . | Worst NYHA . | Metastasis/ progression . | Cumulative anthracycline dose (mg/m2) . | Reason for permanent trastuzumab discontinuation . |
|---|---|---|---|---|---|---|---|---|---|---|
| 43 | 65 | 9 | 67.3 | 46.7 | 24.3 | Yes | II | No | 486* | Symptomatic severe mitral regurgitation |
| 23 | 65 | 9 | 58.2 | 25.9 | 62 | Yes | III | No | 266 | Continuous worsening of LV function with multi-valvular abnormalities |
| 29 | 35 | 12 | 55 | 28 | 47 | No | I | No | 253 | Continuous worsening of LV function |
Note: Oncological outcomes and cardiac characteristics of patients who experience cardiac dose-limiting toxicity (cDLT).
*Patient received high-dose epirubicin as part of the CEF protocol which is no longer in use.17 Epirubicin dose was converted to cardiotoxicity-equivalent doxorubicin dose.16
| ID . | Age . | Number of trastuzumab cycle . | Baseline LVEF (%) . | Nadir LVEF (%) . | Relative GLS drop (%) . | Hospitali- zation . | Worst NYHA . | Metastasis/ progression . | Cumulative anthracycline dose (mg/m2) . | Reason for permanent trastuzumab discontinuation . |
|---|---|---|---|---|---|---|---|---|---|---|
| 43 | 65 | 9 | 67.3 | 46.7 | 24.3 | Yes | II | No | 486* | Symptomatic severe mitral regurgitation |
| 23 | 65 | 9 | 58.2 | 25.9 | 62 | Yes | III | No | 266 | Continuous worsening of LV function with multi-valvular abnormalities |
| 29 | 35 | 12 | 55 | 28 | 47 | No | I | No | 253 | Continuous worsening of LV function |
| ID . | Age . | Number of trastuzumab cycle . | Baseline LVEF (%) . | Nadir LVEF (%) . | Relative GLS drop (%) . | Hospitali- zation . | Worst NYHA . | Metastasis/ progression . | Cumulative anthracycline dose (mg/m2) . | Reason for permanent trastuzumab discontinuation . |
|---|---|---|---|---|---|---|---|---|---|---|
| 43 | 65 | 9 | 67.3 | 46.7 | 24.3 | Yes | II | No | 486* | Symptomatic severe mitral regurgitation |
| 23 | 65 | 9 | 58.2 | 25.9 | 62 | Yes | III | No | 266 | Continuous worsening of LV function with multi-valvular abnormalities |
| 29 | 35 | 12 | 55 | 28 | 47 | No | I | No | 253 | Continuous worsening of LV function |
Note: Oncological outcomes and cardiac characteristics of patients who experience cardiac dose-limiting toxicity (cDLT).
*Patient received high-dose epirubicin as part of the CEF protocol which is no longer in use.17 Epirubicin dose was converted to cardiotoxicity-equivalent doxorubicin dose.16
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
